GLP-1激动剂和运动:未来的生活方式优先级的未来
Roberto Codella1,2, Pamela Senesi2, Livio Luzi1,2
1Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.
Frontiers in clinical diabetes and healthcare
|December 10, 2025
概括
葡萄糖类-1 (GLP-1) 受体激活剂促进体重减轻,但需要炼才能长期维持. 结合这些药物和生活方式的改变,如力量训练和高蛋白摄入量,是有效的肥胖管理的关键.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 心血管科学 心血管科学
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激活剂在减肥和改善代谢和心血管健康方面表现出显著的有效性.
- 它们的有效性往往超过了饮食和运动等生活方式干预措施的有效性.
研究的目的:
- 评估GLP-1受体激动剂在体重管理中的作用.
- 确定是否有必要将药物治疗与生活方式干预相结合,以持续减肥和保持肌肉质量.
主要方法:
- 关于GLP-1受体激动剂和体重管理的最新研究的文献综述.
- 分析运动和饮食改变对体重维持和身体组成与GLP-1疗法结合的影响.
主要成果:
- GLP-1受体激动剂对于初始减肥非常有效.
- 在单独停止GLP-1治疗后,体重恢复是常见的.
- 运动,特别是增加蛋白质摄入量的力量训练,对于长期维持体重和肌肉保存至关重要.
结论:
- 将GLP-1受体激动剂与结构化的生活方式改变相结合的综合方法对于长期的肥胖管理是优越的.
- 未来的战略应侧重于药物治疗,并补充生活方式干预措施,而不是替代药物.
- 运动在减轻肌肉损失和维持使用GLP-1激动剂实现的减肥方面发挥着至关重要的作用.
相关概念视频
Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
Exercise and Cardiovascular Response
3.8K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
3.8K
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
Lifestyle Factors and Health
395
Lifestyle factors play a critical role in maintaining overall health and preventing chronic diseases. Key elements, such as regular physical activity, a nutritious diet, and abstinence from smoking, can significantly enhance physical, mental, and emotional well-being while reducing the risk of several life-threatening conditions.
Benefits of Physical Activity
Physical activity, whether through structured exercise or casual activities like walking, biking, or dancing, is a cornerstone of a...
Benefits of Physical Activity
Physical activity, whether through structured exercise or casual activities like walking, biking, or dancing, is a cornerstone of a...
395
Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562


